Literature DB >> 10071922

Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients.

Y Sato1, K Oizumi, H Kuno, M Kaji.   

Abstract

A 1,25-dihydroxyvitamin D [1,25-(OH)2D] deficiency and immobilization-related increased serum calcium concentration have been observed in hemiplegic stroke patients. To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. Serum concentrations of 25-hydroxyvitamin D [25-(OH)D], 1,25-(OH)2D, ionized calcium, intact parathyroid hormone (PTH), intact bone Gla protein (BGP), and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) were measured. An increased serum calcium concentration (mean 2.543 mEq/L) was observed in this population and correlated negatively with the Barthel index (mean 66), indicating immobilization-induced bone resorption with consequent increased serum calcium. Decreased serum concentrations of 1,25-(OH)2D (mean 25.0 pg/mL) and serum 25-OHD concentration (mean 11.6 ng/mL) were noted. Serum PTH was not increased (mean 34.8 pmol/L). Serum levels of BGP were decreased significantly, whereas serum ICTP concentrations were elevated (mean 15.2 ng/mL). A strong negative correlation was seen between the serum calcium concentration and 1,25-(OH)2D (p < 0.0001). BMD of the second metacarpal in patients was decreased significantly compared with control subjects and highly correlated with 25-(OH)D and 1,25-(OH)2D concentrations. Immobilization-related increased serum calcium levels may inhibit PTH secretion, and thus 1,25-(OH)2D production. In addition, 25-(OH)D insufficiency also may contribute to decreased concentration of 1,25-(OH)2D.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071922     DOI: 10.1016/s8756-3282(98)00185-9

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  4 in total

1.  Alendronate does not prevent long bone fragility in an inactive rat model.

Authors:  K Naruse; K Uchida; M Suto; K Miyagawa; A Kawata; K Urabe; M Takaso; M Itoman; Y Mikuni-Takagaki
Journal:  J Bone Miner Metab       Date:  2015-10-16       Impact factor: 2.626

2.  Rapid long-term bone loss following stroke in a man with osteoporosis and atherosclerosis.

Authors:  Kenneth E S Poole; Elizabeth A Warburton; Jonathan Reeve
Journal:  Osteoporos Int       Date:  2004-06-10       Impact factor: 4.507

3.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

Authors:  P Szulc; P D Delmas
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

Review 4.  Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.

Authors:  Zhao-Ming Zhong; Jian-Ting Chen
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.